Rank |
Status |
Study |
1 |
Unknown †
|
Autonomic Nervous System Alteration Induce by Sepsis: Assessment and Prognosis Impact
Conditions: |
Septic Shock; Severe Sepsis |
Intervention: |
|
Outcome Measures: |
Sinusal variability analysis and myocardic fixation of MIBG performed in 48 hours post admission; plasmatic measure of NT-ProBNP and catecholamine at admission, day 2 and last day of hospitalisation |
|
2 |
Recruiting
|
An Observational Study of the Causes, Management, and Outcomes of Community-acquired Sepsis and Severe Sepsis in Southeast Asia
Conditions: |
Sepsis; Severe Sepsis |
Intervention: |
|
Outcome Measures: |
The etiology of community-acquired Sepsis and severe Sepsis expressed in percentages of enrolled subjects.; The time from hospital admission to any systemic antibiotic administration.; Percentage of initial systemic antimicrobial effective to treat the cause of the infection.; Percentage of subjects receiving fluid challenge (giving bolus of fluid) if the patient has hypotension.; Percentage of subjects receiving adequate ventilatory support (including percentage of subjects receiving supplemental oxygen, percentage of subjects receiving Positive-end Expiratory Pressure (PEEP).; Percentage of subjects receiving low-volume lung-protective ventilation.; Percentage of subjects receiving arterial blood gas evaluation).; Percentage of subjects receiving renal replacement therapies (including hemodialysis and peritoneal dialysis).; Percentage of subjects receiving imaging to determine source or deep foci of infection (including chest radiography, ultrasonogram, CT scan and MRI).; Percentage of subjects receiving evaluation by scoring system.; Percentage of subjects receiving stress prophylaxis.; Percentage of patients receiving deep vein thrombosis (DVT) prophylaxis.; Percentage of subjects receiving treatment in ICUs.; 28-day mortality rate.; Percentage of subjects developing major organ dysfunction; for example ventilatory failure and renal failure.; Risk factors associated with Sepsis or severe Sepsis; Prevalence of antimicrobial resistance and its association with appropriate empirical therapy and outcomes.; Sensitivities and specificities of selected RDTs in determining the causes of community-acquired Sepsis and severe Sepsis |
|
3 |
Not yet recruiting
|
Simplified Severe Sepsis Protocol-2 (SSSP-2) in Zambia
Conditions: |
Sepsis; Severe Sepsis; Tuberculosis |
Interventions: |
Other: Simplified severe Sepsis protocol; Other: Usual care |
Outcome Measures: |
In-hospital all cause mortality; 28-day all-cause mortality; In-hospital all cause mortality adjusted for illness severity; 28-day all cause mortality adjusted for baseline illness severity; Cumulative adverse events; Treatment cost per patient; Antibiotic changed due to culture results |
|
4 |
Unknown †
|
Simplified Severe Sepsis Protocol in Zambia
Conditions: |
Sepsis; Severe Sepsis |
Intervention: |
Other: Simplified Severe Sepsis Protocol |
Outcome Measures: |
In-hospital all cause mortality; 28-day all-cause mortality; In-hospital all cause mortality adjusted for illness severity; 28-day all cause mortality adjusted for baseline illness severity; Cumulative adverse events; Treatment cost per patient; Antibiotic changed due to culture results |
|
5 |
Unknown †
|
Neonatal Sepsis, Evaluation, Bangladesh
Condition: |
Sepsis |
Interventions: |
Other: Amoxycillin, Gentamicin; Other: Counselling |
Outcome Measures: |
Appropriate management of all cases of neonatal Sepsis in the community by community level health care provider; Newborns will be dried and wrapped immediately after birth; Newborns receiving breast feeding within one hour after birth; Newborns first bathed at least three days after birth |
|
6 |
Not yet recruiting
|
Utility of High-Fidelity Simulation In the Education and Assessment of Residents in the Recognition and Management of the Sepsis Syndrome
Conditions: |
Medical Knowledge; Clinical Performance |
Intervention: |
Other: Debriefing of high-fidelity Sepsis simulation scenarios |
Outcome Measures: |
Performance on a written assessment of the recognition and management of early Sepsis in the hospitalized patient.; Performance on a practical assessment of the recognition and management of early Sepsis in the hospitalized patient.; Self-assessment of knowledge and ability in the recognition and management of early Sepsis in the hospitalized patient. |
|
7 |
Unknown †
|
Endothelium in Severe Sepsis
Conditions: |
Sepsis; Severe Sepsis; Septic Shock |
Intervention: |
|
Outcome Measures: |
Mortality; Organ Dysfunction assessed by Sepsis-related Organ Failure Assessment (SOFA) Score |
|
8 |
Unknown †
|
Observational Study of Sepsis and Pneumonia to Develop Diagnostic Tests
Conditions: |
Sepsis; Septicemia; Sepsis Syndrome; Shock, Septic; Community Acquired Pneumonia |
Intervention: |
|
Outcome Measures: |
Death; Septic Shock; Severe Sepsis; Time to death; Time to severe Sepsis; Severe Sepsis; Time to septic shock; Septic shock; Cryptic shock (ScvO2<65 or Lactate >2.5 and MAP >65 mmHg [>18 years of age] or SBP >90 [<18 years of age]); Time to Cryptic shock (ScvO2<65 or Lactate >2.5 and MAP >65 mmHg [>18 years of age] or SBP >90 [<18 years of age]); Hospitalization; Length of hospital stay; ICU admission; Length of ICU admission; Disposition; Renal dysfunction; Respiratory dysfunction; Hematology dysfunction; Metabolic dysfunction; Renal SOFA score; Lung SOFA score; Coagulation SOFA score; Liver SOFA score; CVS SOFA score; Time to respiratory SOFA Score; Time to coagulation SOFA score; Time to liver SOFA score; Time to CVS SOFA score; Time to Renal SOFA score; DIC score >5 (modified ISTH scoring system); Time to DIC score > 5; Development of ALI; Development of ARDS; Time to ALI; Time to ARDS; Ventilator; Ventilator days; MELD score; Effect of early goal directed therapy on primary and secondary end-points; Effect of Activated Protein C on primary and secondary end-points; Effect of stress-dose corticosteroids on primary and secondary end-points; Effect of intensive glycemic control on primary and secondary end-points; APACHE II score; PRISM III score; SOFA score; CAP mortality; CAP and severe Sepsis; CAP and septic shock; Severe CAP (ATS criteria); Severe CAP (BTS criteria); Pneumococcal Sepsis; Staphylococcus aureus Sepsis; Gram negative rod Sepsis; Fungal Sepsis; SeptiFast result; Microbiologic culture result; Urinary legionella antigen; Microbiologic culture; CAP, time to death; CAP, mortality; CAP, time to severe Sepsis; CAP, severe Sepsis; CAP, time to septic shock; CAP, septic shock; Time to severe CAP (ATS and BTS criteria); Severe CAP (ATS and BTS criteria); CAP, mechanical ventilation; CAP, time to mechanical ventilation; CAP, length of mechanical ventilation; CAP, SOFA respiratory score > 2; CAP, respiratory component of severe Sepsis criteria; CAP, hospitalized; CAP, length of hospitalization; CAP, ICU admission; CAP, length of ICU stay; CAP, Disposition; CAP, ALI; CAP, ARDS; CAP, time to ARDS; CAP, time to ALI; CAP, PORT score |
|
9 |
Unknown †
|
Evaluation of Corticosteroid Therapy in Childhood Severe Sepsis - a Randomised Pilot Study
Conditions: |
Paediatric Sepsis; Pediatric Sepsis |
Intervention: |
Drug: hydrocortisone |
Outcome Measures: |
primary efficacy endpoint is all cause mortality; primary toxicity endpoint is Serious Adverse Events, excluding Sepsis-related events specified as secondary outcomes; PIM2; PELOD; ICU mortality; time until shock reversal, defined as cessation of inotropic support for 24 hours; time to resolution of multiorgan dysfunction; time to resolution of base deficit; time to resolution of lactate; time to decision to discharge from ICU; laboratory analysis of adrenal function; laboratory analysis of inflammatory parameters (defined in protocol); laboratory analysis of coagulation parameters (defined in protocol) |
|
10 |
Recruiting
|
Neutropenic Fever, Inflammatory Markers and Sepsis in Haematological Patients
Condition: |
Sepsis |
Intervention: |
Other: Severe Sepsis vs. non-severe Sepsis |
Outcome Measure: |
This study evaluates epidemiology, microbiology and outcome of neutropenic fever and severe Sepsis in haematological patients with special reference to the kinetics of inflammatory markers. |
|
11 |
Unknown †
|
Urinary Proteomics Analysis for Sepsis and Prognosis
Conditions: |
SIRS; Sepsis |
Intervention: |
|
Outcome Measure: |
Survival status |
|
12 |
Unknown †
|
Serum Proteomics Analysis for Sepsis
Conditions: |
SIRS; Sepsis; Severe Sepsis; Death |
Intervention: |
|
Outcome Measure: |
Survival status |
|
13 |
Recruiting
|
Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock
Conditions: |
Severe Sepsis; Septic Shock; Bacteremia |
Intervention: |
|
Outcome Measure: |
The effect of antibiotic administration on blood culture positivity in patients with severe Sepsis and septic shock: a prospective multicenter observational trial. |
|
14 |
Unknown †
|
Muscle Atrophy in Sepsis
Conditions: |
Atrophy; Sepsis; Weakness |
Intervention: |
|
Outcome Measures: |
Electrical stimulation will be associated with upregulation of anabolic signaling molecules and genes, downregulation of catabolic signaling molecules and genes within skeletal muscle of patients with Sepsis; Electrical stimulation will be associated with improvement of histologic and electrophysiologic and strength parameters within skeletal muscle of patients with Sepsis |
|
15 |
Recruiting
|
Lotta Alla Sepsi Ospedaliera - Fighting Hospital Sepsis
Condition: |
Severe Sepsis |
Intervention: |
|
Outcome Measures: |
An improvement in Sepsis Six Bundle implementation for Severe Sepsis and Septic Shock; All cause Mortality |
|
16 |
Unknown †
|
Assessment of Peritoneal Immune Response in Patients With Severe Intra-abdominal Sepsis Managed With Laparostomy and Vacuum Assisted Closure (VAC)
Condition: |
Abdominal Sepsis |
Intervention: |
|
Outcome Measures: |
Measure peritoneal immune response to intra-abdominal Sepsis; General characteristics |
|
17 |
Recruiting
|
Identification Sepsis Related Single Nucleotide Polymorphism (SNP) by Whole Exome Sequencing
Condition: |
Sepsis |
Intervention: |
|
Outcome Measure: |
Sepsis related SNP site |
|
18 |
Unknown †
|
Neonatal Sepsis and GBS Carriage Study
Conditions: |
Neonatal Sepsis; Maternal GBS Carriage |
Intervention: |
|
Outcome Measures: |
Incidence of early onset neonatal Sepsis (including the prevalence of culture positive and culture negative EO GBS Sepsis); Perinatal risk factors for early onset neonatal Sepsis; Prevalence of maternal GBS carriage; GBS serotype specific antibody prevalence; serotypes and antibiotic susceptibility profile of carried and invasive GBS strains |
|
19 |
Recruiting
|
The AVERT Sepsis Investigation
Conditions: |
Sepsis; Severe Sepsis |
Intervention: |
|
Outcome Measure: |
Progressive organ failure |
|
20 |
Not yet recruiting
|
Angiotensin II Antagonist in Severe Sepsis
Condition: |
Severe Sepsis |
Intervention: |
Drug: Irbesartan |
Outcome Measures: |
mortality; Incidence of altered organ function in Sepsis patients measured by SOFA score (Sequential Organ Failure Assessment score) |
|